Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

A Phase 1 Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-04937319 In Adult Patients With Type 2 Diabetes Mellitus (t2dm)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01272804

Enrollment

Registered

2011-01-10

Start date

2011-02-28

Completion date

2011-07-31

Last updated

2017-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2, NIDDM

Keywords

Pharmacokinetics PK Pharmacodynamics PD T2DM Phase 1 Type 2 diabetes mellitus safety and tolerability

Brief summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-04937319 following multiple (14 days) escalating oral doses in patients with type 2 diabetes.

Interventions

DRUGPF-04937319

Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.

DRUGPlacebo

Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients with type 2 diabetes mellitus who are taking metformin only. * Treatment should be stable, where this is defined as no change in the treatment, including dose, over the past 2 months. Regimens may include once daily and twice daily dosing only. * Male and/or female patients (females will be women of non childbearing potential) * Body Mass Index (BMI) of 18.5 to 45.0 kg/m2; and a total body weight \>50 kg (110 lbs). * HbA1c between 7.0% and 10.0%.

Exclusion criteria

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Patients who have chronic conditions other than T2DM (for example, hypercholesterolemia or hypertension) but are controlled by either diet or stable (for the last 2 months) doses of medications may be included as well (for example, a subject with hypercholesterolemia on appropriate treatment is eligible). * Evidence or history of diabetic complications with significant end organ damage, eg, proliferative retinopathy and/or macular edema, creatinine clearance less than 60 mL/min * Any condition possibly affecting drug absorption (eg, gastrectomy) * History of stroke or transient ischemic attack or myocardial infarction within the past 6 months * History of coronary artery bypass graft or stent implantation. * Clinically significant peripheral vascular disease (eg, manifested by claudication). * Any history or clinical evidence of congestive heart failure, NYHA Classes II to IV. * One or more self reported significant/severe/requiring treatment episodes of hypoglycemia within the last 3 months, or two or more self reported significant/severe/requiring treatment episodes of hypoglycaemia within the last 6 months. * Current history of angina/unstable angina. * Milk or soy allergy

Design outcomes

Primary

Measure	Time frame	Description
Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14	-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 14 (fasted condition)	Percent change from baseline in area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 (fasted condition)	AUCtau is the area under the plasma concentration versus time curve from time zero (pre-dose) to the end of the dosing interval (tau), here dosing interval is 24 hours.
Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)	—
Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)	—
Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14	0 hour (pre-dose) through 24 hours post-dose on Day 14	Percentage of drug excreted unchanged in urine calculated as overall amount of unchanged drug excreted in the urine over the dosing interval (24 hours) divided by total daily dose multiplied by 100.
Apparent Oral Clearance (CL/F) on Day 14	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)	Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Apparent Volume of Distribution (Vz/F) on Day 14	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Observed Accumulation Ratio for AUCtau (Rac)	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 and Day 14 (fasted condition)	Accumulation ratio for AUCtau (Rac) was calculated as area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1. Dosing interval = 24 hours.
Observed Accumulation Ratio for Cmax (Rac, Cmax)	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 and Day 14 (fasted condition)	Accumulation ratio for Cmax (Rac, Cmax) was calculated as maximum observed plasma concentration (Cmax) on Day 14 divided by maximum observed plasma concentration (Cmax) on Day 1.
Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1	-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 (fasted condition)	Percent change from baseline in area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.
Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16 hours post morning dose on Day 14 (fasted condition)	—
Plasma Decay Half-Life (t1/2) on Day 14	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24, 36, 48 hours post morning dose on Day 14 (fasted condition)	Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)	AUCtau, ss = Area under the plasma concentration versus time curve from time zero (pre-dose) to the end of the dosing interval (tau) at steady state, here dosing interval is 24 hours.
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Baseline (Day 1) up to 14 days after last dose of study treatment (up to 28 days)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.
Maximum Observed Plasma Concentration (Cmax) On Day 1	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours (hrs) post morning dose on Day 1 (fasted condition)	—
Maximum Observed Plasma Concentration (Cmax) On Day 6	0 (pre-dose), 0.5, 1.5, 3, 5, 8 hours post-dose on Day 6 (fed condition)	—
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1	0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 (fasted condition)	—
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6	0 (pre-dose), 0.5, 1.5, 3, 5, 8 hours post-dose on Day 6 (fed condition)	—

Secondary

Measure	Time frame	Description
Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 and 14 (fasted condition)	Percent change from baseline in area under the plasma insulin concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.
Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 and 14 (fasted condition)	Percent change from baseline in area under the plasma C-peptide concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.
Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	-46, -44, -42, -40, -38, -36, -30, -27 hrs pre-dose on Day -1; 2, 6, 8, 10, 12,18,21 hrs post-dose on Day 1, 6 and 14; additional 0 hr (pre-dose) on Day 6 and 4 hr post-dose on Day 1 and 14	Glucometer testing performed by finger-stick at 8 time points per day to measure glucose levels. Average plasma glucose was calculated as area under the plasma glucose concentration-time curve from 0 to 24 hours (AUC \[0-24\]) divided by 24.
Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Baseline (Pre-dose on Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15	—
Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)	Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.
Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)	Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.
Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)	Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.
Change From Baseline in Lactate Level at Day 6 and 14	Baseline (Day 1), Day 6 and 14	Baseline value was collected at 0 hour on Day 1 for lactate.
Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)	Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.

Countries

United States

Participant flow

Participants by arm

Arm	Count
PF-04937319 10 mg Participants received PF-04937319 10 milligram (mg) tablet orally once daily for 14 days.	9
PF-04937319 30 mg Participants received PF-04937319 30 mg (3 tablets of 10 mg) orally once daily for 14 days.	9
PF-04937319 50 mg Participants received PF-04937319 50 mg (5 tablets of 10 mg) orally once daily for 14 days.	9
PF-04937319 100 mg Participants received PF-04937319 100 mg tablet orally once daily for 14 days.	9
PF-04937319 300 mg Participants received PF-04937319 300 mg (3 tablets of 100 mg) orally once daily for 14 days.	9
Placebo Participants received placebo matched to PF-04937319 tablet orally once daily for 14 days.	16
Total	61

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005
Overall Study	Adverse Event	1	0	0	0	2	1

Baseline characteristics

Characteristic	PF-04937319 50 mg	PF-04937319 100 mg	PF-04937319 300 mg	Placebo	Total	PF-04937319 10 mg	PF-04937319 30 mg
Age, Continuous	54.2 years STANDARD_DEVIATION 5.4	51.4 years STANDARD_DEVIATION 10.6	56.4 years STANDARD_DEVIATION 5.8	57.3 years STANDARD_DEVIATION 5.8	54.4 years STANDARD_DEVIATION 7.7	55.6 years STANDARD_DEVIATION 9.2	49.4 years STANDARD_DEVIATION 7.8
Gender Female	2 Participants	3 Participants	3 Participants	6 Participants	18 Participants	4 Participants	0 Participants
Gender Male	7 Participants	6 Participants	6 Participants	10 Participants	43 Participants	5 Participants	9 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	6 / 9	5 / 9	0 / 9	3 / 9	8 / 9	5 / 16
serious Total, serious adverse events	0 / 9	0 / 9	0 / 9	0 / 9	0 / 9	0 / 16

Outcome results

Primary

Apparent Oral Clearance (CL/F) on Day 14

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)

Population: PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04937319 10 mg	Apparent Oral Clearance (CL/F) on Day 14	21.86 liter per hour	Geometric Coefficient of Variation 25
PF-04937319 30 mg	Apparent Oral Clearance (CL/F) on Day 14	32.32 liter per hour	Geometric Coefficient of Variation 23
PF-04937319 50 mg	Apparent Oral Clearance (CL/F) on Day 14	26.48 liter per hour	Geometric Coefficient of Variation 34
PF-04937319 100 mg	Apparent Oral Clearance (CL/F) on Day 14	31.56 liter per hour	Geometric Coefficient of Variation 37
PF-04937319 300 mg	Apparent Oral Clearance (CL/F) on Day 14	40.29 liter per hour	Geometric Coefficient of Variation 43

Primary

Apparent Volume of Distribution (Vz/F) on Day 14

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04937319 10 mg	Apparent Volume of Distribution (Vz/F) on Day 14	205.3 liter	Geometric Coefficient of Variation 20
PF-04937319 30 mg	Apparent Volume of Distribution (Vz/F) on Day 14	311.6 liter	Geometric Coefficient of Variation 32
PF-04937319 50 mg	Apparent Volume of Distribution (Vz/F) on Day 14	236.7 liter	Geometric Coefficient of Variation 27
PF-04937319 100 mg	Apparent Volume of Distribution (Vz/F) on Day 14	314.0 liter	Geometric Coefficient of Variation 28
PF-04937319 300 mg	Apparent Volume of Distribution (Vz/F) on Day 14	475.2 liter	Geometric Coefficient of Variation 48

Primary

Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14

AUCtau, ss = Area under the plasma concentration versus time curve from time zero (pre-dose) to the end of the dosing interval (tau) at steady state, here dosing interval is 24 hours.

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04937319 10 mg	Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14	458.0 nanogram*hour per milliliter	Geometric Coefficient of Variation 35
PF-04937319 30 mg	Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14	928.7 nanogram*hour per milliliter	Geometric Coefficient of Variation 23
PF-04937319 50 mg	Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14	1889 nanogram*hour per milliliter	Geometric Coefficient of Variation 52
PF-04937319 100 mg	Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14	3167 nanogram*hour per milliliter	Geometric Coefficient of Variation 40
PF-04937319 300 mg	Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14	7446 nanogram*hour per milliliter	Geometric Coefficient of Variation 42

Primary

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1

AUCtau is the area under the plasma concentration versus time curve from time zero (pre-dose) to the end of the dosing interval (tau), here dosing interval is 24 hours.

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 (fasted condition)

Population: PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04937319 10 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1	407.0 nanogram*hour per milliliter	Geometric Coefficient of Variation 29
PF-04937319 30 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1	867.7 nanogram*hour per milliliter	Geometric Coefficient of Variation 21
PF-04937319 50 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1	1456 nanogram*hour per milliliter	Geometric Coefficient of Variation 48
PF-04937319 100 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1	2749 nanogram*hour per milliliter	Geometric Coefficient of Variation 38
PF-04937319 300 mg	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1	6034 nanogram*hour per milliliter	Geometric Coefficient of Variation 40

Primary

Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04937319 10 mg	Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14	51.09 ng/mL	Geometric Coefficient of Variation 27
PF-04937319 30 mg	Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14	79.30 ng/mL	Geometric Coefficient of Variation 31
PF-04937319 50 mg	Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14	171.3 ng/mL	Geometric Coefficient of Variation 36
PF-04937319 100 mg	Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14	251.5 ng/mL	Geometric Coefficient of Variation 44
PF-04937319 300 mg	Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14	555.9 ng/mL	Geometric Coefficient of Variation 44

Primary

Maximum Observed Plasma Concentration (Cmax) On Day 1

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours (hrs) post morning dose on Day 1 (fasted condition)

Population: Pharmacokinetic (PK) parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04937319 10 mg	Maximum Observed Plasma Concentration (Cmax) On Day 1	38.22 nanogram per milliliter (ng/mL)	Geometric Coefficient of Variation 25
PF-04937319 30 mg	Maximum Observed Plasma Concentration (Cmax) On Day 1	69.49 nanogram per milliliter (ng/mL)	Geometric Coefficient of Variation 32
PF-04937319 50 mg	Maximum Observed Plasma Concentration (Cmax) On Day 1	119.4 nanogram per milliliter (ng/mL)	Geometric Coefficient of Variation 38
PF-04937319 100 mg	Maximum Observed Plasma Concentration (Cmax) On Day 1	245.4 nanogram per milliliter (ng/mL)	Geometric Coefficient of Variation 42
PF-04937319 300 mg	Maximum Observed Plasma Concentration (Cmax) On Day 1	449.3 nanogram per milliliter (ng/mL)	Geometric Coefficient of Variation 39

Primary

Maximum Observed Plasma Concentration (Cmax) On Day 6

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8 hours post-dose on Day 6 (fed condition)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04937319 10 mg	Maximum Observed Plasma Concentration (Cmax) On Day 6	57.73 ng/mL	Geometric Coefficient of Variation 17
PF-04937319 30 mg	Maximum Observed Plasma Concentration (Cmax) On Day 6	122.3 ng/mL	Geometric Coefficient of Variation 17
PF-04937319 50 mg	Maximum Observed Plasma Concentration (Cmax) On Day 6	234.1 ng/mL	Geometric Coefficient of Variation 24
PF-04937319 100 mg	Maximum Observed Plasma Concentration (Cmax) On Day 6	421.5 ng/mL	Geometric Coefficient of Variation 31
PF-04937319 300 mg	Maximum Observed Plasma Concentration (Cmax) On Day 6	970.6 ng/mL	Geometric Coefficient of Variation 35

Primary

Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16 hours post morning dose on Day 14 (fasted condition)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04937319 10 mg	Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14	1.380 ng/mL	Geometric Coefficient of Variation 83
PF-04937319 30 mg	Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14	10.56 ng/mL	Geometric Coefficient of Variation 43
PF-04937319 50 mg	Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14	22.73 ng/mL	Geometric Coefficient of Variation 103
PF-04937319 100 mg	Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14	41.68 ng/mL	Geometric Coefficient of Variation 64
PF-04937319 300 mg	Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14	129.8 ng/mL	Geometric Coefficient of Variation 62

Primary

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 14 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.

Time frame: Baseline (Day 1) up to 14 days after last dose of study treatment (up to 28 days)

Population: Safety analysis set included all participants who received at least 1 dose of study medication.

Arm	Measure	Group	Value (NUMBER)
PF-04937319 10 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	0 participants
PF-04937319 10 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	6 participants
PF-04937319 30 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	0 participants
PF-04937319 30 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	5 participants
PF-04937319 50 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	0 participants
PF-04937319 50 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	0 participants
PF-04937319 100 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	0 participants
PF-04937319 100 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	3 participants
PF-04937319 300 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	8 participants
PF-04937319 300 mg	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	0 participants
Placebo	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	0 participants
Placebo	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	5 participants

Primary

Observed Accumulation Ratio for AUCtau (Rac)

Accumulation ratio for AUCtau (Rac) was calculated as area under the curve from time zero to end of dosing interval (AUCtau) on Day 14 divided by area under the curve from time zero to end of dosing interval (AUCtau) on Day 1. Dosing interval = 24 hours.

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 and Day 14 (fasted condition)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04937319 10 mg	Observed Accumulation Ratio for AUCtau (Rac)	1.204 ratio	Geometric Coefficient of Variation 22
PF-04937319 30 mg	Observed Accumulation Ratio for AUCtau (Rac)	1.069 ratio	Geometric Coefficient of Variation 15
PF-04937319 50 mg	Observed Accumulation Ratio for AUCtau (Rac)	1.296 ratio	Geometric Coefficient of Variation 24
PF-04937319 100 mg	Observed Accumulation Ratio for AUCtau (Rac)	1.152 ratio	Geometric Coefficient of Variation 22
PF-04937319 300 mg	Observed Accumulation Ratio for AUCtau (Rac)	1.118 ratio	Geometric Coefficient of Variation 40

Primary

Observed Accumulation Ratio for Cmax (Rac, Cmax)

Accumulation ratio for Cmax (Rac, Cmax) was calculated as maximum observed plasma concentration (Cmax) on Day 14 divided by maximum observed plasma concentration (Cmax) on Day 1.

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 and Day 14 (fasted condition)

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04937319 10 mg	Observed Accumulation Ratio for Cmax (Rac, Cmax)	1.414 ratio	Geometric Coefficient of Variation 41
PF-04937319 30 mg	Observed Accumulation Ratio for Cmax (Rac, Cmax)	1.141 ratio	Geometric Coefficient of Variation 28
PF-04937319 50 mg	Observed Accumulation Ratio for Cmax (Rac, Cmax)	1.437 ratio	Geometric Coefficient of Variation 17
PF-04937319 100 mg	Observed Accumulation Ratio for Cmax (Rac, Cmax)	1.026 ratio	Geometric Coefficient of Variation 25
PF-04937319 300 mg	Observed Accumulation Ratio for Cmax (Rac, Cmax)	1.080 ratio	Geometric Coefficient of Variation 40

Primary

Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14

Percentage of drug excreted unchanged in urine calculated as overall amount of unchanged drug excreted in the urine over the dosing interval (24 hours) divided by total daily dose multiplied by 100.

Time frame: 0 hour (pre-dose) through 24 hours post-dose on Day 14

Arm	Measure	Value (MEAN)	Dispersion
PF-04937319 10 mg	Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14	0.3904 percentage of dose	Standard Deviation 0.11901
PF-04937319 30 mg	Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14	0.3533 percentage of dose	Standard Deviation 0.20183
PF-04937319 50 mg	Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14	0.6463 percentage of dose	Standard Deviation 0.56717
PF-04937319 100 mg	Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14	0.5380 percentage of dose	Standard Deviation 0.34593
PF-04937319 300 mg	Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14	0.4294 percentage of dose	Standard Deviation 0.44676

Primary

Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1

Percent change from baseline in area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.

Time frame: -46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 (fasted condition)

Population: Pharmacodynamic (PD) analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter.

Arm	Measure	Value (MEAN)	Dispersion
PF-04937319 10 mg	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1	-0.46 percent change	Standard Deviation 8.881
PF-04937319 30 mg	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1	-2.67 percent change	Standard Deviation 6.67
PF-04937319 50 mg	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1	6.41 percent change	Standard Deviation 14.532
PF-04937319 100 mg	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1	-12.11 percent change	Standard Deviation 14.225
PF-04937319 300 mg	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1	-12.29 percent change	Standard Deviation 13.711
Placebo	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1	-3.71 percent change	Standard Deviation 10.848

Primary

Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14

Time frame: -46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 14 (fasted condition)

Population: PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.

Arm	Measure	Value (MEAN)	Dispersion
PF-04937319 10 mg	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14	-11.94 percent change	Standard Deviation 15.477
PF-04937319 30 mg	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14	-4.91 percent change	Standard Deviation 16.601
PF-04937319 50 mg	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14	-4.11 percent change	Standard Deviation 17.321
PF-04937319 100 mg	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14	-26.83 percent change	Standard Deviation 21.054
PF-04937319 300 mg	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14	-11.37 percent change	Standard Deviation 15.205
Placebo	Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14	-2.86 percent change	Standard Deviation 12.103

Primary

Plasma Decay Half-Life (t1/2) on Day 14

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24, 36, 48 hours post morning dose on Day 14 (fasted condition)

Arm	Measure	Value (MEAN)	Dispersion
PF-04937319 10 mg	Plasma Decay Half-Life (t1/2) on Day 14	6.563 hour	Standard Deviation 0.77897
PF-04937319 30 mg	Plasma Decay Half-Life (t1/2) on Day 14	6.884 hour	Standard Deviation 1.9264
PF-04937319 50 mg	Plasma Decay Half-Life (t1/2) on Day 14	6.348 hour	Standard Deviation 1.4271
PF-04937319 100 mg	Plasma Decay Half-Life (t1/2) on Day 14	6.960 hour	Standard Deviation 1.0358
PF-04937319 300 mg	Plasma Decay Half-Life (t1/2) on Day 14	8.479 hour	Standard Deviation 2.4173

Primary

Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 14 (fasted condition)

Arm	Measure	Value (MEDIAN)
PF-04937319 10 mg	Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14	3.00 hour
PF-04937319 30 mg	Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14	3.00 hour
PF-04937319 50 mg	Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14	3.00 hour
PF-04937319 100 mg	Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14	3.00 hour
PF-04937319 300 mg	Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14	3.00 hour

Primary

Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8, 12, 16, 24 hours post morning dose on Day 1 (fasted condition)

Population: PK parameter analysis population included all enrolled participants treated with PF-04937319 who had at least 1 of the PK parameters of interest.

Arm	Measure	Value (MEDIAN)
PF-04937319 10 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1	3.00 hour
PF-04937319 30 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1	3.00 hour
PF-04937319 50 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1	3.00 hour
PF-04937319 100 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1	3.00 hour
PF-04937319 300 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1	3.00 hour

Primary

Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6

Time frame: 0 (pre-dose), 0.5, 1.5, 3, 5, 8 hours post-dose on Day 6 (fed condition)

Arm	Measure	Value (MEDIAN)
PF-04937319 10 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6	1.50 hour
PF-04937319 30 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6	1.50 hour
PF-04937319 50 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6	1.50 hour
PF-04937319 100 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6	1.50 hour
PF-04937319 300 mg	Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6	1.50 hour

Secondary

Change From Baseline in Average Plasma Glucose at Day 1, 6, 14

Glucometer testing performed by finger-stick at 8 time points per day to measure glucose levels. Average plasma glucose was calculated as area under the plasma glucose concentration-time curve from 0 to 24 hours (AUC \[0-24\]) divided by 24.

Time frame: -46, -44, -42, -40, -38, -36, -30, -27 hrs pre-dose on Day -1; 2, 6, 8, 10, 12,18,21 hrs post-dose on Day 1, 6 and 14; additional 0 hr (pre-dose) on Day 6 and 4 hr post-dose on Day 1 and 14

Population: PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 PD parameter. Here 'n' signifies participants evaluable for this measure at specified time point for each arm group, respectively.

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04937319 10 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 6 (n=8,9,9,9,7,15)	-19.62 mg/dL	Standard Deviation 16.247
PF-04937319 10 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 1 (n=9,9,9,9,9,16)	-7.18 mg/dL	Standard Deviation 9.851
PF-04937319 10 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Baseline (n=9,9,9,9,9,16)	192.10 mg/dL	Standard Deviation 22.913
PF-04937319 10 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 14 (n=8,9,9,9,7,15)	-12.65 mg/dL	Standard Deviation 25.918
PF-04937319 30 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 1 (n=9,9,9,9,9,16)	-5.24 mg/dL	Standard Deviation 6.421
PF-04937319 30 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Baseline (n=9,9,9,9,9,16)	188.83 mg/dL	Standard Deviation 48.992
PF-04937319 30 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 6 (n=8,9,9,9,7,15)	-6.35 mg/dL	Standard Deviation 22.496
PF-04937319 30 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 14 (n=8,9,9,9,7,15)	-16.45 mg/dL	Standard Deviation 27.709
PF-04937319 50 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Baseline (n=9,9,9,9,9,16)	195.78 mg/dL	Standard Deviation 37.871
PF-04937319 50 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 14 (n=8,9,9,9,7,15)	-14.79 mg/dL	Standard Deviation 33.687
PF-04937319 50 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 6 (n=8,9,9,9,7,15)	9.80 mg/dL	Standard Deviation 30.359
PF-04937319 50 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 1 (n=9,9,9,9,9,16)	8.72 mg/dL	Standard Deviation 15.071
PF-04937319 100 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 14 (n=8,9,9,9,7,15)	-48.87 mg/dL	Standard Deviation 27.216
PF-04937319 100 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 6 (n=8,9,9,9,7,15)	-32.36 mg/dL	Standard Deviation 24.121
PF-04937319 100 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Baseline (n=9,9,9,9,9,16)	205.38 mg/dL	Standard Deviation 44.632
PF-04937319 100 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 1 (n=9,9,9,9,9,16)	-1.90 mg/dL	Standard Deviation 21.784
PF-04937319 300 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Baseline (n=9,9,9,9,9,16)	170.95 mg/dL	Standard Deviation 51.465
PF-04937319 300 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 6 (n=8,9,9,9,7,15)	-47.19 mg/dL	Standard Deviation 25.752
PF-04937319 300 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 14 (n=8,9,9,9,7,15)	-34.15 mg/dL	Standard Deviation 24.596
PF-04937319 300 mg	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 1 (n=9,9,9,9,9,16)	-23.26 mg/dL	Standard Deviation 19.189
Placebo	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 14 (n=8,9,9,9,7,15)	-7.48 mg/dL	Standard Deviation 21.703
Placebo	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 1 (n=9,9,9,9,9,16)	3.04 mg/dL	Standard Deviation 17.611
Placebo	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Change at Day 6 (n=8,9,9,9,7,15)	3.92 mg/dL	Standard Deviation 17.068
Placebo	Change From Baseline in Average Plasma Glucose at Day 1, 6, 14	Baseline (n=9,9,9,9,9,16)	189.07 mg/dL	Standard Deviation 39.131

Secondary

Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

Time frame: Baseline (Pre-dose on Day 1), Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 14 (n=8,9,9,9,7,15)	-33.63 mg/dL	Standard Deviation 26.175
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 15 (n=8,9,9,9,7,15)	-13.38 mg/dL	Standard Deviation 22.595
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 4 (n=9,9,9,9,8,16)	-13.44 mg/dL	Standard Deviation 19.603
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 8 (n=8,9,9,9,7,15)	-23.25 mg/dL	Standard Deviation 21.212
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 7 (n=8,9,9,9,7,15)	-13.50 mg/dL	Standard Deviation 21.314
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 12 (n=8,9,9,9,7,15)	-27.13 mg/dL	Standard Deviation 28.423
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 3 (n=9,9,9,9,9,16)	-19.11 mg/dL	Standard Deviation 10.216
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 11 (n=8,9,9,9,7,15)	-17.38 mg/dL	Standard Deviation 28.54
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 5 (n=9,9,9,9,9,16)	-19.67 mg/dL	Standard Deviation 16.256
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 9 (n=8,9,9,9,7,15)	-19.63 mg/dL	Standard Deviation 20.784
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 2 (n=9,9,9,9,9,16)	-5.00 mg/dL	Standard Deviation 10.84
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Baseline (n=9,9,9,9,9,16)	173.78 mg/dL	Standard Deviation 31.952
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 10 (n=8,9,9,9,7,15)	-23.88 mg/dL	Standard Deviation 23.503
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 13 (n=8,9,9,9,7,15)	-18.13 mg/dL	Standard Deviation 30.258
PF-04937319 10 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 6 (n=9,9,9,9,7,15)	-10.89 mg/dL	Standard Deviation 18.21
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Baseline (n=9,9,9,9,9,16)	181.33 mg/dL	Standard Deviation 50.621
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 2 (n=9,9,9,9,9,16)	-4.67 mg/dL	Standard Deviation 12.845
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 8 (n=8,9,9,9,7,15)	-8.56 mg/dL	Standard Deviation 20.415
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 7 (n=8,9,9,9,7,15)	-12.78 mg/dL	Standard Deviation 13.664
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 14 (n=8,9,9,9,7,15)	-23.67 mg/dL	Standard Deviation 25.441
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 13 (n=8,9,9,9,7,15)	-23.44 mg/dL	Standard Deviation 23.807
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 3 (n=9,9,9,9,9,16)	-5.78 mg/dL	Standard Deviation 10.171
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 6 (n=9,9,9,9,7,15)	-16.33 mg/dL	Standard Deviation 17.804
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 12 (n=8,9,9,9,7,15)	-18.56 mg/dL	Standard Deviation 28.183
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 4 (n=9,9,9,9,8,16)	-9.44 mg/dL	Standard Deviation 16.001
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 15 (n=8,9,9,9,7,15)	-21.44 mg/dL	Standard Deviation 26.034
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 11 (n=8,9,9,9,7,15)	-22.56 mg/dL	Standard Deviation 22.49
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 5 (n=9,9,9,9,9,16)	-9.89 mg/dL	Standard Deviation 15.358
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 10 (n=8,9,9,9,7,15)	-16.89 mg/dL	Standard Deviation 20.847
PF-04937319 30 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 9 (n=8,9,9,9,7,15)	-22.11 mg/dL	Standard Deviation 20.709
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 12 (n=8,9,9,9,7,15)	-16.89 mg/dL	Standard Deviation 41.87
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Baseline (n=9,9,9,9,9,16)	190.11 mg/dL	Standard Deviation 34.505
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 2 (n=9,9,9,9,9,16)	-6.78 mg/dL	Standard Deviation 25.43
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 3 (n=9,9,9,9,9,16)	-18.78 mg/dL	Standard Deviation 27.124
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 4 (n=9,9,9,9,8,16)	-13.78 mg/dL	Standard Deviation 28.9
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 5 (n=9,9,9,9,9,16)	-22.56 mg/dL	Standard Deviation 29.56
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 6 (n=9,9,9,9,7,15)	-18.00 mg/dL	Standard Deviation 34.38
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 7 (n=8,9,9,9,7,15)	-14.44 mg/dL	Standard Deviation 37.27
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 8 (n=8,9,9,9,7,15)	-5.56 mg/dL	Standard Deviation 37.964
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 9 (n=8,9,9,9,7,15)	-9.78 mg/dL	Standard Deviation 42.825
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 10 (n=8,9,9,9,7,15)	-16.33 mg/dL	Standard Deviation 32.427
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 11 (n=8,9,9,9,7,15)	-18.11 mg/dL	Standard Deviation 39.81
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 13 (n=8,9,9,9,7,15)	-24.78 mg/dL	Standard Deviation 40.822
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 14 (n=8,9,9,9,7,15)	-26.56 mg/dL	Standard Deviation 39.768
PF-04937319 50 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 15 (n=8,9,9,9,7,15)	-23.89 mg/dL	Standard Deviation 38.238
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 9 (n=8,9,9,9,7,15)	-24.78 mg/dL	Standard Deviation 17.817
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 6 (n=9,9,9,9,7,15)	-29.11 mg/dL	Standard Deviation 16.027
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 11 (n=8,9,9,9,7,15)	-32.89 mg/dL	Standard Deviation 20.294
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 7 (n=8,9,9,9,7,15)	-30.22 mg/dL	Standard Deviation 16.672
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 13 (n=8,9,9,9,7,15)	-30.89 mg/dL	Standard Deviation 19.548
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 4 (n=9,9,9,9,8,16)	-19.67 mg/dL	Standard Deviation 20.899
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 3 (n=9,9,9,9,9,16)	-13.22 mg/dL	Standard Deviation 15.571
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 15 (n=8,9,9,9,7,15)	-44.11 mg/dL	Standard Deviation 19.586
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 12 (n=8,9,9,9,7,15)	-32.22 mg/dL	Standard Deviation 17.88
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 5 (n=9,9,9,9,9,16)	-26.56 mg/dL	Standard Deviation 21.03
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Baseline (n=9,9,9,9,9,16)	193.67 mg/dL	Standard Deviation 45.695
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 10 (n=8,9,9,9,7,15)	-37.11 mg/dL	Standard Deviation 19.877
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 8 (n=8,9,9,9,7,15)	-24.11 mg/dL	Standard Deviation 19.934
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 2 (n=9,9,9,9,9,16)	-1.78 mg/dL	Standard Deviation 14.507
PF-04937319 100 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 14 (n=8,9,9,9,7,15)	-43.78 mg/dL	Standard Deviation 22.725
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 7 (n=8,9,9,9,7,15)	-43.71 mg/dL	Standard Deviation 18.117
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 15 (n=8,9,9,9,7,15)	-40.57 mg/dL	Standard Deviation 25.553
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 9 (n=8,9,9,9,7,15)	-38.00 mg/dL	Standard Deviation 19.502
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 5 (n=9,9,9,9,9,16)	-30.33 mg/dL	Standard Deviation 22.17
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 10 (n=8,9,9,9,7,15)	-34.29 mg/dL	Standard Deviation 24.452
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 4 (n=9,9,9,9,8,16)	-42.88 mg/dL	Standard Deviation 20.972
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Baseline (n=9,9,9,9,9,16)	162.33 mg/dL	Standard Deviation 50.269
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 11 (n=8,9,9,9,7,15)	-38.57 mg/dL	Standard Deviation 22.24
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 3 (n=9,9,9,9,9,16)	-32.78 mg/dL	Standard Deviation 17.527
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 12 (n=8,9,9,9,7,15)	-43.57 mg/dL	Standard Deviation 26.576
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 13 (n=8,9,9,9,7,15)	-39.71 mg/dL	Standard Deviation 22.706
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 2 (n=9,9,9,9,9,16)	-23.44 mg/dL	Standard Deviation 18.662
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 14 (n=8,9,9,9,7,15)	-41.86 mg/dL	Standard Deviation 22.386
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 8 (n=8,9,9,9,7,15)	-31.71 mg/dL	Standard Deviation 20.155
PF-04937319 300 mg	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 6 (n=9,9,9,9,7,15)	-43.00 mg/dL	Standard Deviation 15.61
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 6 (n=9,9,9,9,7,15)	-8.27 mg/dL	Standard Deviation 12.708
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 13 (n=8,9,9,9,7,15)	-12.27 mg/dL	Standard Deviation 18.718
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 4 (n=9,9,9,9,8,16)	-4.13 mg/dL	Standard Deviation 18.722
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 8 (n=8,9,9,9,7,15)	-4.93 mg/dL	Standard Deviation 16.434
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 14 (n=8,9,9,9,7,15)	-11.80 mg/dL	Standard Deviation 16.545
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 10 (n=8,9,9,9,7,15)	-6.20 mg/dL	Standard Deviation 10.544
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Baseline (n=9,9,9,9,9,16)	172.44 mg/dL	Standard Deviation 42.527
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 15 (n=8,9,9,9,7,15)	-11.47 mg/dL	Standard Deviation 17.916
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 9 (n=8,9,9,9,7,15)	-2.80 mg/dL	Standard Deviation 15.857
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 5 (n=9,9,9,9,9,16)	-14.06 mg/dL	Standard Deviation 21.402
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 12 (n=8,9,9,9,7,15)	-7.73 mg/dL	Standard Deviation 17.91
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 3 (n=9,9,9,9,9,16)	-7.81 mg/dL	Standard Deviation 16.885
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 2 (n=9,9,9,9,9,16)	0.94 mg/dL	Standard Deviation 12.588
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 7 (n=8,9,9,9,7,15)	-5.60 mg/dL	Standard Deviation 12.704
Placebo	Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15	Change at Day 11 (n=8,9,9,9,7,15)	-5.73 mg/dL	Standard Deviation 19.374

Secondary

Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up

Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.

Time frame: Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04937319 10 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-10.50 mg/dL	Standard Deviation 5.78
PF-04937319 10 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-7.63 mg/dL	Standard Deviation 4.21
PF-04937319 10 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-4.00 mg/dL	Standard Deviation 2.65
PF-04937319 10 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-4.89 mg/dL	Standard Deviation 3.98
PF-04937319 10 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-11.0 mg/dL	Standard Deviation 5.1
PF-04937319 10 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-3.56 mg/dL	Standard Deviation 4.1
PF-04937319 10 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	48.11 mg/dL	Standard Deviation 10.96
PF-04937319 30 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-5.78 mg/dL	Standard Deviation 10.59
PF-04937319 30 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	43.33 mg/dL	Standard Deviation 9.51
PF-04937319 30 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-3.67 mg/dL	Standard Deviation 6.36
PF-04937319 30 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-3.44 mg/dL	Standard Deviation 5.98
PF-04937319 30 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-5.78 mg/dL	Standard Deviation 7.61
PF-04937319 30 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-5.22 mg/dL	Standard Deviation 6.5
PF-04937319 30 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-4.33 mg/dL	Standard Deviation 7.73
PF-04937319 50 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	1.33 mg/dL	Standard Deviation 6.75
PF-04937319 50 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	0.00 mg/dL	Standard Deviation 5.15
PF-04937319 50 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-3.22 mg/dL	Standard Deviation 7.24
PF-04937319 50 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	1.22 mg/dL	Standard Deviation 5.7
PF-04937319 50 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	1.00 mg/dL	Standard Deviation 4.66
PF-04937319 50 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	46.44 mg/dL	Standard Deviation 11.51
PF-04937319 50 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-1.56 mg/dL	Standard Deviation 5.7
PF-04937319 100 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-4.22 mg/dL	Standard Deviation 4.12
PF-04937319 100 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-4.44 mg/dL	Standard Deviation 6.98
PF-04937319 100 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-3.11 mg/dL	Standard Deviation 3.69
PF-04937319 100 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-4.56 mg/dL	Standard Deviation 4.07
PF-04937319 100 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-4.44 mg/dL	Standard Deviation 4.93
PF-04937319 100 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-4.44 mg/dL	Standard Deviation 3.21
PF-04937319 100 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	43.89 mg/dL	Standard Deviation 13.66
PF-04937319 300 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-0.67 mg/dL	Standard Deviation 7.07
PF-04937319 300 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	1.14 mg/dL	Standard Deviation 4.49
PF-04937319 300 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-0.86 mg/dL	Standard Deviation 4.38
PF-04937319 300 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	49.44 mg/dL	Standard Deviation 14.05
PF-04937319 300 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	1.00 mg/dL	Standard Deviation 3.79
PF-04937319 300 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-2.29 mg/dL	Standard Deviation 4.07
PF-04937319 300 mg	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-2.43 mg/dL	Standard Deviation 2.64
Placebo	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-3.50 mg/dL	Standard Deviation 6.86
Placebo	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-3.36 mg/dL	Standard Deviation 9.04
Placebo	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-6.93 mg/dL	Standard Deviation 9.52
Placebo	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-3.88 mg/dL	Standard Deviation 8.02
Placebo	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-5.00 mg/dL	Standard Deviation 7.99
Placebo	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-6.20 mg/dL	Standard Deviation 7.8
Placebo	Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	48.94 mg/dL	Standard Deviation 9.33

Secondary

Change From Baseline in Lactate Level at Day 6 and 14

Baseline value was collected at 0 hour on Day 1 for lactate.

Time frame: Baseline (Day 1), Day 6 and 14

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04937319 10 mg	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 6 (n=9,9,9,9,7,15)	-2.44 mg/dL	Standard Deviation 7.95
PF-04937319 10 mg	Change From Baseline in Lactate Level at Day 6 and 14	Baseline (n=9,9,9,9,9,16)	17.64 mg/dL	Standard Deviation 5.14
PF-04937319 10 mg	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 14 (n=8,9,9,9,7,15)	0.21 mg/dL	Standard Deviation 3.07
PF-04937319 30 mg	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 6 (n=9,9,9,9,7,15)	1.02 mg/dL	Standard Deviation 1.77
PF-04937319 30 mg	Change From Baseline in Lactate Level at Day 6 and 14	Baseline (n=9,9,9,9,9,16)	10.17 mg/dL	Standard Deviation 3.07
PF-04937319 30 mg	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 14 (n=8,9,9,9,7,15)	-0.09 mg/dL	Standard Deviation 2.02
PF-04937319 50 mg	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 6 (n=9,9,9,9,7,15)	-2.08 mg/dL	Standard Deviation 7.14
PF-04937319 50 mg	Change From Baseline in Lactate Level at Day 6 and 14	Baseline (n=9,9,9,9,9,16)	14.14 mg/dL	Standard Deviation 7.82
PF-04937319 50 mg	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 14 (n=8,9,9,9,7,15)	-3.88 mg/dL	Standard Deviation 6.63
PF-04937319 100 mg	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 6 (n=9,9,9,9,7,15)	-6.08 mg/dL	Standard Deviation 10.72
PF-04937319 100 mg	Change From Baseline in Lactate Level at Day 6 and 14	Baseline (n=9,9,9,9,9,16)	21.66 mg/dL	Standard Deviation 9.45
PF-04937319 100 mg	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 14 (n=8,9,9,9,7,15)	-6.97 mg/dL	Standard Deviation 10.42
PF-04937319 300 mg	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 6 (n=9,9,9,9,7,15)	2.61 mg/dL	Standard Deviation 6.6
PF-04937319 300 mg	Change From Baseline in Lactate Level at Day 6 and 14	Baseline (n=9,9,9,9,9,16)	11.57 mg/dL	Standard Deviation 4.3
PF-04937319 300 mg	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 14 (n=8,9,9,9,7,15)	2.60 mg/dL	Standard Deviation 2.98
Placebo	Change From Baseline in Lactate Level at Day 6 and 14	Baseline (n=9,9,9,9,9,16)	14.74 mg/dL	Standard Deviation 8.58
Placebo	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 14 (n=8,9,9,9,7,15)	-2.59 mg/dL	Standard Deviation 8.67
Placebo	Change From Baseline in Lactate Level at Day 6 and 14	Change at Day 6 (n=9,9,9,9,7,15)	-1.45 mg/dL	Standard Deviation 9.27

Secondary

Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up

Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.

Time frame: Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04937319 10 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-17.13 mg/dL	Standard Deviation 21.14
PF-04937319 10 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-8.78 mg/dL	Standard Deviation 23.21
PF-04937319 10 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,8,9,9,7,16)	-6.22 mg/dL	Standard Deviation 24.4
PF-04937319 10 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	116.67 mg/dL	Standard Deviation 37.41
PF-04937319 10 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-19.22 mg/dL	Standard Deviation 22.22
PF-04937319 10 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-17.88 mg/dL	Standard Deviation 22.22
PF-04937319 10 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-19.00 mg/dL	Standard Deviation 24.94
PF-04937319 30 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-22.44 mg/dL	Standard Deviation 16.49
PF-04937319 30 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-11.44 mg/dL	Standard Deviation 16.84
PF-04937319 30 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,8,9,9,7,16)	-10.38 mg/dL	Standard Deviation 15.15
PF-04937319 30 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-5.89 mg/dL	Standard Deviation 19.37
PF-04937319 30 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	133.56 mg/dL	Standard Deviation 43.47
PF-04937319 30 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-20.44 mg/dL	Standard Deviation 22.32
PF-04937319 30 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-15.00 mg/dL	Standard Deviation 14.11
PF-04937319 50 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-13.67 mg/dL	Standard Deviation 14.74
PF-04937319 50 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	123.44 mg/dL	Standard Deviation 35.72
PF-04937319 50 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-6.89 mg/dL	Standard Deviation 15.26
PF-04937319 50 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-30.89 mg/dL	Standard Deviation 14.08
PF-04937319 50 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-19.89 mg/dL	Standard Deviation 14.68
PF-04937319 50 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-20.22 mg/dL	Standard Deviation 16.75
PF-04937319 50 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,8,9,9,7,16)	-27.11 mg/dL	Standard Deviation 22.05
PF-04937319 100 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	130.67 mg/dL	Standard Deviation 33.83
PF-04937319 100 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-6.67 mg/dL	Standard Deviation 19.46
PF-04937319 100 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-2.33 mg/dL	Standard Deviation 22.11
PF-04937319 100 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-7.89 mg/dL	Standard Deviation 17.92
PF-04937319 100 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-11.56 mg/dL	Standard Deviation 17.92
PF-04937319 100 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-0.67 mg/dL	Standard Deviation 16.86
PF-04937319 100 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,8,9,9,7,16)	-19.78 mg/dL	Standard Deviation 22.97
PF-04937319 300 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-11.00 mg/dL	Standard Deviation 23.51
PF-04937319 300 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,8,9,9,7,16)	-17.43 mg/dL	Standard Deviation 16.7
PF-04937319 300 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-0.29 mg/dL	Standard Deviation 38.98
PF-04937319 300 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	96.11 mg/dL	Standard Deviation 37.88
PF-04937319 300 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-9.57 mg/dL	Standard Deviation 35.69
PF-04937319 300 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-3.86 mg/dL	Standard Deviation 38.21
PF-04937319 300 mg	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-1.00 mg/dL	Standard Deviation 38.18
Placebo	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	5.79 mg/dL	Standard Deviation 27.5
Placebo	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	4.80 mg/dL	Standard Deviation 30.59
Placebo	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-3.63 mg/dL	Standard Deviation 14.8
Placebo	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	2.73 mg/dL	Standard Deviation 20.35
Placebo	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	102.44 mg/dL	Standard Deviation 31.64
Placebo	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,8,9,9,7,16)	-2.25 mg/dL	Standard Deviation 23.61
Placebo	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	5.07 mg/dL	Standard Deviation 24.99

Secondary

Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up

Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.

Time frame: Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04937319 10 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-30.00 mg/dL	Standard Deviation 24.51
PF-04937319 10 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-19.44 mg/dL	Standard Deviation 25.73
PF-04937319 10 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-26.38 mg/dL	Standard Deviation 26.72
PF-04937319 10 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	200.56 mg/dL	Standard Deviation 34.32
PF-04937319 10 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-31.50 mg/dL	Standard Deviation 21.08
PF-04937319 10 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-19.11 mg/dL	Standard Deviation 20.95
PF-04937319 10 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-24.00 mg/dL	Standard Deviation 17.21
PF-04937319 30 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-25.11 mg/dL	Standard Deviation 19.47
PF-04937319 30 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-14.67 mg/dL	Standard Deviation 14.4
PF-04937319 30 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-12.44 mg/dL	Standard Deviation 24.7
PF-04937319 30 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-9.33 mg/dL	Standard Deviation 13.46
PF-04937319 30 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-29.11 mg/dL	Standard Deviation 14.42
PF-04937319 30 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-22.11 mg/dL	Standard Deviation 13.6
PF-04937319 30 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	207.33 mg/dL	Standard Deviation 41.11
PF-04937319 50 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-29.44 mg/dL	Standard Deviation 27.13
PF-04937319 50 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-14.22 mg/dL	Standard Deviation 16.93
PF-04937319 50 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-20.78 mg/dL	Standard Deviation 19.39
PF-04937319 50 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-30.89 mg/dL	Standard Deviation 17.41
PF-04937319 50 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	205.00 mg/dL	Standard Deviation 50.52
PF-04937319 50 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-27.44 mg/dL	Standard Deviation 17.08
PF-04937319 50 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-29.11 mg/dL	Standard Deviation 20.26
PF-04937319 100 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-16.33 mg/dL	Standard Deviation 18.33
PF-04937319 100 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-33.56 mg/dL	Standard Deviation 40.73
PF-04937319 100 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-12.11 mg/dL	Standard Deviation 24.49
PF-04937319 100 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-11.33 mg/dL	Standard Deviation 21.17
PF-04937319 100 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	213.22 mg/dL	Standard Deviation 53.38
PF-04937319 100 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-15.11 mg/dL	Standard Deviation 20.76
PF-04937319 100 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-24.22 mg/dL	Standard Deviation 25.73
PF-04937319 300 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-11.56 mg/dL	Standard Deviation 31.13
PF-04937319 300 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	170.22 mg/dL	Standard Deviation 41.37
PF-04937319 300 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-2.29 mg/dL	Standard Deviation 41.43
PF-04937319 300 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	1.29 mg/dL	Standard Deviation 41.63
PF-04937319 300 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	1.86 mg/dL	Standard Deviation 45.05
PF-04937319 300 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	0.00 mg/dL	Standard Deviation 42.9
PF-04937319 300 mg	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-15.29 mg/dL	Standard Deviation 8.24
Placebo	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-5.50 mg/dL	Standard Deviation 29.57
Placebo	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-6.47 mg/dL	Standard Deviation 26.19
Placebo	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	0.33 mg/dL	Standard Deviation 30
Placebo	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-7.50 mg/dL	Standard Deviation 18.4
Placebo	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	181.94 mg/dL	Standard Deviation 34.45
Placebo	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-1.43 mg/dL	Standard Deviation 32.9
Placebo	Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-6.60 mg/dL	Standard Deviation 37.37

Secondary

Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up

Blood sample for lipid biomarker was taken following 12-hours fasting. Baseline value was collected on Day -2 for lipids.

Time frame: Baseline (Day -2), Day 3, 6, 10, 14, 16 and Follow-up (7 to 14 days after last dose of study medication)

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04937319 10 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-41.22 mg/dL	Standard Deviation 73.73
PF-04937319 10 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-19.25 mg/dL	Standard Deviation 76.2
PF-04937319 10 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-5.89 mg/dL	Standard Deviation 82.19
PF-04937319 10 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	13.25 mg/dL	Standard Deviation 108.99
PF-04937319 10 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	178.89 mg/dL	Standard Deviation 63.21
PF-04937319 10 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-32.00 mg/dL	Standard Deviation 70.4
PF-04937319 10 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-16.88 mg/dL	Standard Deviation 58.15
PF-04937319 30 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	1.67 mg/dL	Standard Deviation 63.16
PF-04937319 30 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	1.78 mg/dL	Standard Deviation 66.28
PF-04937319 30 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	152.33 mg/dL	Standard Deviation 43.88
PF-04937319 30 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-1.33 mg/dL	Standard Deviation 65.02
PF-04937319 30 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-4.44 mg/dL	Standard Deviation 65.79
PF-04937319 30 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-6.67 mg/dL	Standard Deviation 80.27
PF-04937319 30 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	38.78 mg/dL	Standard Deviation 163.3
PF-04937319 50 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-44.44 mg/dL	Standard Deviation 45.88
PF-04937319 50 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	4.56 mg/dL	Standard Deviation 73.52
PF-04937319 50 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-6.44 mg/dL	Standard Deviation 59.39
PF-04937319 50 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-36.22 mg/dL	Standard Deviation 50.27
PF-04937319 50 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-37.33 mg/dL	Standard Deviation 48.75
PF-04937319 50 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-40.44 mg/dL	Standard Deviation 50.85
PF-04937319 50 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	175.56 mg/dL	Standard Deviation 53.32
PF-04937319 100 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	-25.44 mg/dL	Standard Deviation 59.99
PF-04937319 100 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	192.78 mg/dL	Standard Deviation 91.62
PF-04937319 100 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-29.00 mg/dL	Standard Deviation 62.9
PF-04937319 100 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	-13.56 mg/dL	Standard Deviation 51.83
PF-04937319 100 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-40.33 mg/dL	Standard Deviation 55.72
PF-04937319 100 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-35.33 mg/dL	Standard Deviation 53.61
PF-04937319 100 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	-45.44 mg/dL	Standard Deviation 120.43
PF-04937319 300 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	23.57 mg/dL	Standard Deviation 50.04
PF-04937319 300 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	30.71 mg/dL	Standard Deviation 43.77
PF-04937319 300 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	22.29 mg/dL	Standard Deviation 57.79
PF-04937319 300 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	13.14 mg/dL	Standard Deviation 51.5
PF-04937319 300 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	0.22 mg/dL	Standard Deviation 42.4
PF-04937319 300 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	123.33 mg/dL	Standard Deviation 47.89
PF-04937319 300 mg	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	15.57 mg/dL	Standard Deviation 38.25
Placebo	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Baseline (n=9,9,9,9,9,16)	152.31 mg/dL	Standard Deviation 70.46
Placebo	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 10 (n=8,9,9,9,7,15)	2.13 mg/dL	Standard Deviation 46.04
Placebo	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 3 (n=9,9,9,9,9,16)	0.88 mg/dL	Standard Deviation 47.31
Placebo	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 6 (n=9,9,9,9,7,15)	-14.67 mg/dL	Standard Deviation 51.85
Placebo	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 16 (n=8,9,9,9,7,14)	-19.07 mg/dL	Standard Deviation 47.96
Placebo	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Day 14 (n=8,9,9,9,7,15)	-21.67 mg/dL	Standard Deviation 44.03
Placebo	Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up	Change at Follow-up (n=9,9,9,9,7,16)	1.94 mg/dL	Standard Deviation 52.43

Secondary

Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14

Percent change from baseline in area under the plasma C-peptide concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.

Time frame: -46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 and 14 (fasted condition)

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04937319 10 mg	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	-2.36 percent change	Standard Deviation 10.17
PF-04937319 10 mg	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	8.66 percent change	Standard Deviation 11.069
PF-04937319 30 mg	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	8.53 percent change	Standard Deviation 13.383
PF-04937319 30 mg	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	13.49 percent change	Standard Deviation 14.403
PF-04937319 50 mg	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	12.65 percent change	Standard Deviation 9.974
PF-04937319 50 mg	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	16.51 percent change	Standard Deviation 27.962
PF-04937319 100 mg	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	2.37 percent change	Standard Deviation 12.421
PF-04937319 100 mg	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	-1.44 percent change	Standard Deviation 14.463
PF-04937319 300 mg	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	16.34 percent change	Standard Deviation 8.94
PF-04937319 300 mg	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	22.50 percent change	Standard Deviation 14.809
Placebo	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	-1.43 percent change	Standard Deviation 9.488
Placebo	Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	1.80 percent change	Standard Deviation 16.722

Secondary

Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14

Percent change from baseline in area under the plasma insulin concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.

Time frame: -46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1 and 14 (fasted condition)

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04937319 10 mg	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	-2.22 percent change	Standard Deviation 17.843
PF-04937319 10 mg	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	15.77 percent change	Standard Deviation 21.452
PF-04937319 30 mg	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	13.24 percent change	Standard Deviation 22.221
PF-04937319 30 mg	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	17.98 percent change	Standard Deviation 26.499
PF-04937319 50 mg	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	24.11 percent change	Standard Deviation 13.772
PF-04937319 50 mg	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	30.86 percent change	Standard Deviation 41.063
PF-04937319 100 mg	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	4.41 percent change	Standard Deviation 17.47
PF-04937319 100 mg	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	0.38 percent change	Standard Deviation 21.14
PF-04937319 300 mg	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	18.10 percent change	Standard Deviation 17.059
PF-04937319 300 mg	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	39.23 percent change	Standard Deviation 26.876
Placebo	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 1 (n=9,9,9,9,9,16)	-2.92 percent change	Standard Deviation 15.768
Placebo	Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14	Percent Change at Day 14 (n=8,9,9,9,7,15)	7.62 percent change	Standard Deviation 26.034

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Apparent Oral Clearance (CL/F) on Day 14

Apparent Volume of Distribution (Vz/F) on Day 14

Area Under the Curve From Time Zero to End of Dosing Interval at Steady State (AUCtau, ss) on Day 14

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) on Day 1

Maximum Observed Plasma Concentration at Steady State (Cmax, ss) On Day 14

Maximum Observed Plasma Concentration (Cmax) On Day 1

Maximum Observed Plasma Concentration (Cmax) On Day 6

Minimum Observed Plasma Trough Concentration at Steady State (Cmin, ss) on Day 14

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Observed Accumulation Ratio for AUCtau (Rac)

Observed Accumulation Ratio for Cmax (Rac, Cmax)

Percentage of Unchanged Drug Excreted in the Urine Over Dosing Interval (Ae[%]) on Day 14

Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1

Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 14

Plasma Decay Half-Life (t1/2) on Day 14

Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax, ss) on Day 14

Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1

Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 6

Change From Baseline in Average Plasma Glucose at Day 1, 6, 14

Change From Baseline in Fasting Plasma Glucose at Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up

Change From Baseline in Lactate Level at Day 6 and 14

Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) Level at Day 3, 6, 10, 14, 16 and Follow-up

Change From Baseline in Total Cholesterol (TC) Level at Day 3, 6, 10, 14, 16 and Follow-up

Change From Baseline in Triglyceride (TG) Level at Day 3, 6, 10, 14, 16 and Follow-up

Percent Change From Baseline in C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14

Percent Change From Baseline in Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1 and 14